Updated on 2022/03/18

写真a

 
IMAI Norihiro
 
Organization
Nagoya University Hospital Diagnostic and Therapeutic Endoscopy Assistant professor of hospital
Title
Assistant professor of hospital
External link

Degree 1

  1. Doctor of Philosophy (Medical Science) ( 2016.3   Nagoya University ) 

Professional Memberships 5

  1. 日本内科学会

  2. 日本消化器病学会

  3. 日本消化器内視鏡学会

  4. 日本肝臓学会

  5. American Association for the Study of Liver Diseases

Awards 7

  1. American Heart Association Postdoctoral Fellowship

    2019   American Heart Association  

     More details

  2. Best Poster Award, Postdoc Research Day

    2019   Weill Cornell Medicine, The Postdoctoral Association  

  3. Irwin M. Arias, MD Postdoctoral Research Fellowship Award

    2018   American Liver Foundation  

     More details

    Country:United States

  4. 2015 Best Poster Award, the 120th annual meeting of the Japanese Association of Anatomists

    2015   the 120th Annual Meeting of The Japanese Association of Anatomists, the 92nd Annual Meeting of The Physiological Society of Japan   UBXD8 deletion in hepatocytes induced more evident abnormalities in female than in male mice

     More details

    Award type:Award from Japanese society, conference, symposium, etc.  Country:Japan

  5. Presidential Poster of Distinction

    2015   American Association for the Study of Liver Disease  

     More details

    Award type:Award from international society, conference, symposium, etc.  Country:United States

  6. International Young Investigator Travel Award

    2015   American Association for the Study of Liver Disease  

     More details

    Award type:Award from international society, conference, symposium, etc.  Country:United States

  7. Young Investigator Award of Nagoya University Internal Medicine

    2015  

     More details

    Country:Japan

▼display all

 

Papers 53

  1. Changes in Body Composition Predict the Time to Treatment Failure of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma: A Pilot Retrospective Study.

    Yamamoto T, Imai N, Kuzuya T, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishigami M

    Nutrition and cancer     page: 1 - 10   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1080/01635581.2022.2049322

    PubMed

  2. Patients with low muscle mass have characteristic microbiome with low potential for amino acid synthesis in chronic liver disease.

    Yamamoto K, Ishizu Y, Honda T, Ito T, Imai N, Nakamura M, Kawashima H, Kitaura Y, Ishigami M, Fujishiro M

    Scientific reports   Vol. 12 ( 1 ) page: 3674   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41598-022-07810-3

    PubMed

  3. Obesity and myosteatosis: the two characteristics of dynapenia in patients with cirrhosis.

    Sugiyama Y, Ishizu Y, Ando Y, Yokoyama S, Yamamoto K, Ito T, Imai N, Nakamura M, Honda T, Kawashima H, Ishikawa T, Ishigami M

    European journal of gastroenterology & hepatology   Vol. 33 ( 1S Suppl 1 ) page: e916 - e921   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:European journal of gastroenterology & hepatology  

    OBJECTIVE: In patients with liver cirrhosis, the clinical characteristics of dynapenia, a condition in which skeletal muscle mass is maintained but muscle strength is reduced, are not yet known. This study aimed to clarify the characteristics of dynapenia and its impact on quality of life (QOL) in patients with liver cirrhosis. METHODS: We retrospectively analyzed 116 patients with cirrhosis. Based on grip strength and skeletal muscle mass measured by the bioelectrical impedance analysis method, patients were divided into four groups: normal muscle status, dynapenia, pre-sarcopenia (a condition involving only low muscle mass), and sarcopenia. The characteristics of dynapenia and its influence on QOL were examined. RESULTS: Fourteen patients had dynapenia. Liver function did not differ among the four groups. In patients with dynapenia, BMI was highest and computed tomography attenuation of skeletal muscle at the third lumbar spine vertebra was lowest among the four groups. The percentage of patients with both BMI ≥25 kg/m2 and myosteatosis was significantly higher in patients with dynapenia [9/14 (64.3%)] than in those with sarcopenia [2/23 (8.7%), P = 0.004] and pre-sarcopenia [0/18 (0%), P < 0.001] and tended to be higher than those with normal muscle status [16/61 (26.2%), P = 0.065]. The physical QOL in patients with dynapenia was as low as that in those with sarcopenia and significantly lower than that in those with normal muscle status. CONCLUSION: Cirrhotic patients with dynapenia had high BMI and myosteatosis, and impaired physical QOL.

    DOI: 10.1097/MEG.0000000000002303

    Scopus

    PubMed

  4. Nuclear Receptor CoRepressors, NCOR1 and SMRT, are required for maintaining systemic metabolic homeostasis

    Ritter Megan J., Amano Izuki, Imai Norihiro, De Oliveira Lorraine Soares, Vella Kristen R., Hollenberg Anthony N.

    MOLECULAR METABOLISM   Vol. 53   page: 101315   2021.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Molecular Metabolism  

    Objective: The nuclear receptor corepressor 1 (NCOR1) and the silencing mediator of retinoic acid and thyroid hormone (SMRT, also known as NCOR2) play critical and specific roles in nuclear receptor action. NCOR1, both in vitro and in vivo specifically regulates thyroid hormone (TH) action in the context of individual organs such as the liver, and systemically in the context of the hypothalamic-pituitary-thyroid (HPT) axis. In contrast, selective deletion of SMRT in the liver or globally has shown that it plays very little role in TH signaling. However, both NCOR1 and SMRT have some overlapping roles in hepatic metabolism and lipogenesis. Here, we determine the roles of NCOR1 and SMRT in global physiologic function and find if SMRT could play a compensatory role in the regulation of TH action, globally. Methods: We used a postnatal deletion strategy to disrupt both NCOR1 and SMRT together in all tissues at 8–9 weeks of age in male and female mice. This was performed using a tamoxifen-inducible Cre recombinase (UBC-Cre-ERT2) to KO (knockout) NCOR1, SMRT, or NCOR1 and SMRT together. We used the same strategy to KO HDAC3 in male and female mice of the same age. Metabolic parameters, gene expression, and thyroid function tests were analyzed. Results: Surprisingly, adult mice that acquired NCOR1 and SMRT deletion rapidly became hypoglycemic and hypothermic and perished within ten days of deletion of both corepressors. Postnatal deletion of either NCOR1 or SMRT had no impact on mortality. NCOR1/SMRT KO mice rapidly developed hepatosteatosis and mild elevations in liver function tests. Additionally, alterations in lipogenesis, beta oxidation, along with hepatic triglyceride and glycogen levels suggested defects in hepatic metabolism. The intestinal function was intact in the NCOR1/SMRT knockout (KO) mice. The KO of HDAC3 resulted in a distinct phenotype from the NCOR1/SMRT KO mice, whereas none of the HDAC3 KO mice succumbed after tamoxifen injection. Conclusions: The KO of NCOR1 and SMRT rapidly leads to significant metabolic abnormalities that do not survive – including hypoglycemia, hypothermia, and weight loss. Hepatosteatosis rapidly developed along with alterations in hepatic metabolism suggesting a contribution to the dramatic phenotype from liver injury. Glucose production and absorption were intact in NCOR1/SMRT KO mice, demonstrating a multifactorial process leading to their demise. HDAC3 KO mice have a distinct phenotype from the NCOR1/SMRT KO mice—which implies that NCOR1/SMRT together regulate a critical pathway that is required for survival in adulthood and is separate from HDAC3.

    DOI: 10.1016/j.molmet.2021.101315

    Web of Science

    Scopus

    PubMed

  5. Safety and Efficacy of Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Hepatocellular Carcinoma: First Clinical Outcomes

    Imai Norihiro, Yokoyama Shinya, Yamamoto Kenta, Ito Takanori, Ishizu Yoji, Honda Takashi, Ishigami Masatoshi

    ANTICANCER RESEARCH   Vol. 41 ( 11 ) page: 5817 - 5820   2021.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Anticancer Research  

    Aim: Novel glass membrane pumping emulsification devices (GMDs) enable the formation of a high-percentage water-in-oil emulsion with homogeneous and stable droplets. Although GMDs are expected to improve therapeutic effects in transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC), clinical outcomes are not yet available. Patients and Methods: A total of 26 patients with unresectable HCC who underwent TACE using a GMD were analyzed retrospectively. Ethiodized oil was mixed with epirubicin solution using a GMD. The emulsion was injected into the tumor-feeding artery, followed by embolization. Results: The median size of HCCs was 28 (range=15-60) mm, and 15 nodules were solitary. Overall treatment effects were complete response in 18 cases (90%) and partial response in two (10%). The local recurrence rate at 6 months was 24.2%. No major complication was observed except for grade 4 elevations of liver enzymes in one case. Conclusion: TACE using a GMD is effective and safe in clinical practice.

    DOI: 10.21873/anticanres.15399

    Web of Science

    Scopus

    PubMed

  6. The absence of large portal collateral vessels is concerned with spontaneous improvement of cirrhotic portal vein thrombosis.

    Yokoyama S, Ishizu Y, Honda T, Imai N, Ito T, Yamamoto K, Tomoyuki T, Ishigami M

    Hepatology research : the official journal of the Japan Society of Hepatology     2021.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/hepr.13725

    PubMed

  7. Immune-related liver injury is a poor prognostic factor in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.

    Yamamoto T, Ito T, Hase T, Ishigami M, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Shibata H, Hatta T, Yogo N, Yasuda S, Toyoda H, Abe T, Kawashima H, Hashimoto N, Fujishiro M

    Cancer investigation     page: 1 - 31   2021.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1080/07357907.2021.1994586

    PubMed

  8. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies

    Ito Takanori, Ishigami Masatoshi, Yamamoto Takafumi, Mizuno Kazuyuki, Yamamoto Kenta, Imai Norihiro, Ishizu Yoji, Honda Takashi, Kawashima Hiroki, Yasuda Satoshi, Toyoda Hidenori, Yokota Kenji, Hase Tetsunari, Nishio Naoki, Maeda Osamu, Kato Masashi, Hashimoto Naozumi, Hibi Hideharu, Kodera Yasuhiro, Sone Michihiko, Ando Yuichi, Akiyama Masashi, Shimoyama Yoshie, Fujishiro Mitsuhiro

    HEPATOLOGY INTERNATIONAL   Vol. 15 ( 5 ) page: 1278 - 1287   2021.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Hepatology International  

    Background: The clinical course of liver injury induced by immune checkpoint inhibitors (ICIs) varies among individuals, and there were few reports on the therapeutic effects of corticosteroids based on the patterns of liver injury. Methods: We evaluated the characteristics and clinical course of immune-related liver injury in 1214 patients treated with ICIs for advanced malignancies except for hepatocellular carcinoma between August 2014 and May 2021. Results: During the follow-up period (median, 252 days), 58 patients (4.8%) had an immune-related liver injury (≥ Grade 3). The liver-injury patterns were hepatocellular (n = 26, 44.8%), mixed (n = 11, 19.0%), or cholestatic (n = 21, 36.2%), and the median time to onset of liver injury was 39, 81, and 53 days, respectively; the hepatocellular pattern occurred earlier than the other types (p = 0.047). Corticosteroids were administered to 30 (51.7%) patients; while liver injury was improved in almost all patients with the hepatocellular pattern (n = 13/14, 92.9%), that failed to show improvement in over half of the patients with the non-hepatocellular patterns, and three patients with mixed patterns needed secondary immunosuppression with mycophenolate mofetil. Liver biopsies performed in 13 patients mainly showed lobular injury, endothelialitis, and spotty necrosis with infiltration of T cells positive for CD3 and CD8, but not CD4 or CD20. Conclusion: The incidence pattern and therapeutic response to corticosteroids in immune-related liver injury differ according to the injury type. Although corticosteroids were effective for the hepatocellular pattern, an additional strategy for refractory non-hepatocellular patterns is needed.

    DOI: 10.1007/s12072-021-10238-y

    Web of Science

    Scopus

    PubMed

  9. USEFULNESS OF CORE I97L IN PREDICTING THE EFFICACY OF NUCLEOS(T)IDE ANALOGUE THERAPY IN PATIENTS WITH HEPATITIS B

    TakashiHonda, MasatoshiIshigami, ShinyaYokoyama, Yamamoto Kenta, Ito Takanori, Imai Norihiro, Ishizu Yoji, Ishikawa Tetsuya, Fujishiro Mitsuhiro

    HEPATOLOGY   Vol. 74   page: 468A - 469A   2021.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Web of Science

  10. The influence of hepatitis C virus eradication on hepatocarcinogenesis in patients with hemophiliaHCC after HCV eradication in hemophilia.

    Inukai Y, Imai N, Yamamoto K, Ito T, Ishizu Y, Honda T, Okamoto S, Kanematsu T, Suzuki N, Matsushita T, Ishigami M, Fujishiro M

    Annals of hepatology   Vol. 27 ( 1 ) page: 100545   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Annals of Hepatology  

    Introduction and objectives: Hepatitis C virus (HCV) infections in patients with hemophilia lead to the development of hepatocellular carcinoma (HCC) at a relatively younger age than that in patients without hemophilia. Although recent progress in direct-acting-antivirals has facilitated a high rate of sustained virological response (SVR), the clinical influence of HCV eradication in hemophilia patients remains unclear. This study aimed to compare the clinical outcomes of SVR against HCV in patients with and without hemophilia. Patients and methods: The study enrolled 699 patients who achieved SVR after HCV antiviral treatment. Patients were divided into two groups: 78 patients with hemophilia (H group) and 621 patients without hemophilia (NH group). We evaluated patient characteristics, clinical outcomes, and the cumulative incidence of HCC after SVR. Results: Compared with the NH group, patients in the H-group were significantly younger and had a lower hepatic fibrosis score. No difference was found in the incidence of liver-related disease or overall death between the two groups over a mean follow-up period of 7 years. Four patients in the H group and 36 patients in the NH group were diagnosed with HCC after SVR. Multivariate analysis showed that male sex, age, and cirrhosis were significant risk factors for HCC incidence. There was no significant difference in the cumulative incidence of HCC after propensity-score matching adjusting for the risk factors of HCC between the two groups. Conclusion: Hemophilia is not a significant risk factor for hepatocarcinogenesis after SVR against HCV.

    DOI: 10.1016/j.aohep.2021.100545

    Scopus

    PubMed

  11. Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the Gut-Liver axis

    Muto Hisanori, Ito Takanori, Tanaka Taku, Yokoyama Shinya, Yamamoto Kenta, Imai Norihiro, Ishizu Yoji, Maeda Keiko, Honda Takashi, Ishikawa Tetsuya, Kato Asuka, Ohshiro Taichi, Kano Fumiya, Yamamoto Akihito, Sakai Kiyoshi, Hibi Hideharu, Ishigami Masatoshi, Fujishiro Mitsuhiro

    SCIENTIFIC REPORTS   Vol. 11 ( 1 ) page: 18778   2021.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Scientific Reports  

    Non-alcoholic steatohepatitis (NASH) occurrence has been increasing and is becoming a major cause of liver cirrhosis and liver cancer. However, effective treatments for NASH are still lacking. We examined the benefits of serum-free conditioned medium from stem cells derived from human exfoliated deciduous teeth (SHED-CM) on a murine non-alcoholic steatohepatitis (NASH) model induced by a combination of Western diet (WD) and repeated administration of low doses of carbon tetrachloride intraperitoneally, focusing on the gut-liver axis. We showed that repeated intravenous administration of SHED-CM significantly ameliorated histological liver fibrosis and inflammation in a murine NASH model. SHED-CM inhibited parenchymal cell apoptosis and reduced the activation of inflammatory macrophages. Gene expression of pro-inflammatory and pro-fibrotic mediators (such as Tnf-α, Tgf-β, and Ccl-2) in the liver was reduced in mice treated with SHED-CM. Furthermore, SHED-CM protected intestinal tight junctions and maintained intestinal barrier function, while suppressing gene expression of the receptor for endotoxin, Toll-like receptor 4, in the liver. SHED-CM promoted the recovery of Caco-2 monolayer dysfunction induced by IFN-γ and TNF-α in vitro. Our findings suggest that SHED-CM may inhibit NASH fibrosis via the gut-liver axis, in addition to its protective effect on hepatocytes and the induction of macrophages with unique anti-inflammatory phenotypes.

    DOI: 10.1038/s41598-021-98254-8

    Web of Science

    Scopus

    PubMed

  12. Revisiting Prognosis After Liver Transplant in Patients Positive for Hepatitis C Virus: Focus on Hepatitis C Recurrence-Unrelated Complications

    Ishigami Masatoshi, Honda Takashi, Ishizu Yoji, Imai Norihiro, Ito Takanori, Yamamoto Kenta, Kamei Hideya, Ogura Yasuhiro, Fujishiro Mitsuhiro

    EXPERIMENTAL AND CLINICAL TRANSPLANTATION   Vol. 19 ( 9 ) page: 935 - 942   2021.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Experimental and Clinical Transplantation  

    Objectives: In this study, we revisited the reasons for poorer prognosis after liver transplant in patients with hepatitis C virus, whose main causes of death were generally known to be recurrent disease. Materials and Methods: Between April 2003 and March 2017, among 132 patients who underwent liver transplant because of liver cirrhosis at our institution, 40 patients (30.3%) were positive for hepatis C virus. We retrospectively compared the overall survival after liver transplant in patients with and without hepatitis C virus infection. Furthermore, we investigated the causes of death in transplant recipients with hepatitis C virus infections. Results: In patients with hepatitis C virus infection, overall survival was 82.2%, 75.2%, and 50.8% at 1, 5, and 10 years, respectively, after liver transplant; these results were lower than those in patients without infection (94.5%, 87.0%, and 87.0% at 1, 5, and 10 years, respectively; P = .001). Among 40 patients with positive infection, 14 patients died after liver transplant. A main reason for death was hepatocellular carcinoma recurrence (3 patients). Surprisingly, only 1 patient died from hepatitis C virus-related complication (fibrosing cholestatic hepatitis); the remaining 10 patients died from reasons other than hepatitis C virus disease progression. Conclusions: Our results suggest that clinicians should not only be aware of hepatitis C virus recurrence but should also be aware of other unrelated complications in transplant recipients who are positive for this virus.

    DOI: 10.6002/ect.2021.0197

    Web of Science

    Scopus

    PubMed

  13. Upregulation of Thioesterase Superfamily Member 2 in Skeletal Muscle Promotes Hepatic Steatosis and Insulin Resistance.

    Imai N, Nicholls HT, Alves-Bezerra M, Li Y, Ivanova AA, Ortlund EA, Cohen DE

    Hepatology (Baltimore, Md.)     2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/hep.32122

    PubMed

  14. The impact of hepatitis C virus eradication on hepatocarcinogenesis in haemophiliacs

    Inukai Yosuke, Imai Norihiro, Yamamoto Kenta, Ito Takanori, Ishizu Yoji, Honda Takashi, Ishigami Masatoshi

    JOURNAL OF HEPATOLOGY   Vol. 75   page: S787 - S788   2021.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Web of Science

  15. Thioesterase superfamily member 1 undergoes stimulus-coupled conformational reorganization to regulate metabolism in mice

    Li Yue, Imai Norihiro, Nicholls Hayley T., Roberts Blaine R., Goyal Samaksh, Krisko Tibor I., Ang Lay-Hong, Tillman Matthew C., Roberts Anne M., Baqai Mahnoor, Ortlund Eric A., Cohen David E., Hagen Susan J.

    NATURE COMMUNICATIONS   Vol. 12 ( 1 ) page: 3493   2021.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Nature Communications  

    In brown adipose tissue, thermogenesis is suppressed by thioesterase superfamily member 1 (Them1), a long chain fatty acyl-CoA thioesterase. Them1 is highly upregulated by cold ambient temperature, where it reduces fatty acid availability and limits thermogenesis. Here, we show that Them1 regulates metabolism by undergoing conformational changes in response to β-adrenergic stimulation that alter Them1 intracellular distribution. Them1 forms metabolically active puncta near lipid droplets and mitochondria. Upon stimulation, Them1 is phosphorylated at the N-terminus, inhibiting puncta formation and activity and resulting in a diffuse intracellular localization. We show by correlative light and electron microscopy that Them1 puncta are biomolecular condensates that are inhibited by phosphorylation. Thus, Them1 forms intracellular biomolecular condensates that limit fatty acid oxidation and suppress thermogenesis. During a period of energy demand, the condensates are disrupted by phosphorylation to allow for maximal thermogenesis. The stimulus-coupled reorganization of Them1 provides fine-tuning of thermogenesis and energy expenditure.

    DOI: 10.1038/s41467-021-23595-x

    Web of Science

    Scopus

    PubMed

  16. Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs.

    Yamamoto T, Imai N, Yamamoto K, Ito T, Ishizu Y, Honda T, Okamoto S, Kanematsu T, Suzuki N, Matsushita T, Ishigami M, Fujishiro M

    Anticancer research   Vol. 41 ( 5 ) page: 2569 - 2573   2021.5

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.15035

    PubMed

  17. Impact of visceral fat accumulation on the prognosis of patients with cirrhosis

    Ishizu Yoji, Ishigami Masatoshi, Honda Takashi, Imai Norihiro, Ito Takanori, Yamamoto Kenta, Fujishiro Mitsuhiro

    CLINICAL NUTRITION ESPEN   Vol. 42   page: 354 - 360   2021.4

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Clinical Nutrition ESPEN  

    DOI: 10.1016/j.clnesp.2021.01.008

    Web of Science

    Scopus

    PubMed

    researchmap

  18. Progression After Molecular Targeted Agents: Hepatic Arterial Changes and Transarterial Chemoembolization in Hepatocellular Carcinoma.

    Matsuda N, Imai N, Kuzuya T, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishigami M, Fujishiro M

    In vivo (Athens, Greece)   Vol. 35 ( 2 ) page: 1185 - 1189   2021.3

     More details

    Publishing type:Research paper (scientific journal)   Publisher:In Vivo  

    DOI: 10.21873/invivo.12367

    Scopus

    PubMed

    researchmap

  19. Safety and efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma patients with haemophilia

    Yamamoto Takafumi, Imai Norihiro, Yamamoto Kenta, Ito Takanori, Ishizu Yoji, Honda Takashi, Okamoto Shuichi, Kanematsu Takeshi, Suzuki Nobuaki, Matsushita Tadashi, Ishigami Masatoshi, Fujishiro Mitsuhiro

    HAEMOPHILIA   Vol. 27 ( 1 ) page: 100 - 107   2021.1

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Haemophilia  

    DOI: 10.1111/hae.14220

    Web of Science

    Scopus

    PubMed

    researchmap

  20. The albumin-bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC

    Ito Takanori, Ishigami Masatoshi, Morooka Hikaru, Yamamoto Kenta, Imai Norihiro, Ishizu Yoji, Honda Takashi, Nishimura Daisaku, Tada Toshifumi, Yasuda Satoshi, Toyoda Hidenori, Kumada Takashi, Fujishiro Mitsuhiro

    SCIENTIFIC REPORTS   Vol. 10 ( 1 ) page: 17812   2020.10

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Scientific Reports  

    DOI: 10.1038/s41598-020-74732-3

    Web of Science

    Scopus

    PubMed

    researchmap

  21. Allosteric regulation of thioesterase superfamily member 1 by lipid sensor domain binding fatty acids and lysophosphatidylcholine

    Tillman Matthew C., Imai Norihiro, Li Yue, Khadka Manoj, Okafor C. Denise, Juneja Puneet, Adhiyaman Akshitha, Hagen Susan J., Cohen David E., Ortlund Eric A.

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA   Vol. 117 ( 36 ) page: 22080 - 22089   2020.9

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Proceedings of the National Academy of Sciences of the United States of America  

    DOI: 10.1073/pnas.2003877117

    Web of Science

    Scopus

    PubMed

    researchmap

  22. Them1 Binds to Free Fatty Acids and is Allosterically Regulated by Lysophosphatidylcholine to Control Fatty Acyl-CoA Hydrolysis in Brown Adipose Tissue

    Tillman Matthew, Li Yue, Khadka Manoj, Imai Norihiro, Adhiyaman Akshitha, Juneja Puneet, Hagen Susan, Cohen David, Ortlund Eric

    FASEB JOURNAL   Vol. 34   2020.4

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1096/fasebj.2020.34.s1.07311

    Web of Science

    researchmap

  23. Thioesterase Superfamily Member 1 Undergoes Stimulus-coupled Reorganization to Regulate Metabolic Activity in Brown Adipose Tissue

    Li Yue, Imai Norihiro, Goyal Samaksh, Nicholls Hayley, Krisko Tibor, Baqai Mahnoor, Ang Lay-Hong, Tillman Matthew, Ortlund Eric, Cohen David, Hagen Susan

    FASEB JOURNAL   Vol. 34   2020.4

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1096/fasebj.2020.34.s1.04503

    Web of Science

    researchmap

  24. Hepatology Highlights.

    Shah PA, Lau DTY, Russo NW, Brown RS Jr, Maiers JL, Schwartz RE, Imai N, Krisko TI, Navarro-Corcuera A, Jalan-Sakrikar N, Pisa JF, Jesudian AB, Tafesh ZH, Fortune BE, Kostallari E

    Hepatology (Baltimore, Md.)   Vol. 71 ( 1 ) page: 1 - 3   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/hep.31072

    PubMed

    researchmap

  25. Trimming the Fat: Acetyl-CoA Carboxylase Inhibition for the Management of NAFLD.

    Imai N, Cohen DE

    Hepatology (Baltimore, Md.)   Vol. 68 ( 6 ) page: 2062 - 2065   2018.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/hep.30206

    Web of Science

    Scopus

    PubMed

    researchmap

  26. Hepatocyte-specific depletion of ubiquitin regulatory X domain containing protein 8 accelerates fibrosis in a mouse non-alcoholic steatohepatitis model

    Imai Norihiro, Suzuki Michitaka, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Hayashi Kazuhiko, Ishigami Masatoshi, Hirooka Yoshiki, Ishikawa Tetsuya, Goto Hidemi, Fujimoto Toyoshi

    HISTOCHEMISTRY AND CELL BIOLOGY   Vol. 148 ( 3 ) page: 219 - 227   2017.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00418-017-1572-6

    Web of Science

    Scopus

    PubMed

    researchmap

  27. Hepatocyte-Specific Depletion of UBXD8 Induces Periportal Steatosis in Mice Fed a High-Fat Diet

    Imai Norihiro, Suzuki Michitaka, Hayashi Kazuhiko, Ishigami Masatoshi, Hirooka Yoshiki, Abe Takaya, Shioi Go, Goto Hidemi, Fujimoto Toyoshi

    PLOS ONE   Vol. 10 ( 5 ) page: e0127114   2015.5

     More details

    Publishing type:Research paper (scientific journal)   Publisher:PLoS ONE  

    DOI: 10.1371/journal.pone.0127114

    Web of Science

    Scopus

    PubMed

    researchmap

  28. Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques.

    Imai N, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Hirooka Y, Goto H

    World journal of hepatology   Vol. 6 ( 12 ) page: 844 - 50   2014.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.4254/wjh.v6.i12.844

    Scopus

    PubMed

    researchmap

  29. The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma

    KUZUYA Teiji, ISHIGAMI Masatoshi, NIINOMI Takurou, IMAI Norihiro, ACHIWA Kouichi, ARAKAWA Takahiro, YAMADA Keiichi, NAKANO Satoshi, ISHIZU Yoji, HONDA Takashi, HAYASHI Kazuhiko, ISHIKAWA Tetsuya, NAKANO Isao, KATANO Yoshiaki, ITOH Akihiro, HIROOKA Yoshiki, GOTO Hidemi

    Kanzo   Vol. 54 ( 7 ) page: 505 - 506   2013.5

     More details

    Publishing type:Research paper (scientific journal)   Publisher:The Japan Society of Hepatology  

    We investigated the relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma (HCC). Subjects were 64 patients who began sorafenib therapy. Contrast enhanced CT images were taken at baseline and after 2 weeks of sorafenib treatment. In patients with fever, the ratio of patients demonstrating the disappearance or decrease of lesion contrast on contrast enhanced CT images was significantly higher than in those without fever (91.3% and 61.0%, respectively, p=0.010, Fisher's exact probability test). The results suggested the relationship between the fever and contrast change on contrast enhanced CT.<br>

    DOI: 10.2957/kanzo.54.505

    Scopus

    researchmap

  30. Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases.

    Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

    Gut and liver   Vol. 7 ( 2 ) page: 246 - 51   2013.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.5009/gnl.2013.7.2.246

    Scopus

    PubMed

    researchmap

  31. Clinical trial of percutaneous radio frequency ablation therapy by two-step insertion method using VirtuTRAX<sup>TM</sup> instrument navigator

    Kuzuya Teiji, Hayashi Kazuhiko, Ishigami Masatoshi, Ishikawa Tetsuya, Nakano Isao, Katano Yoshiaki, Itoh Akihiro, Hirooka Yoshiki, Izumi Namiki, Goto Hidemi, Ishizu Yoji, Niinomi Takurou, Imai Norihiro, Achiwa Kouichi, Arakawa Takahiro, Yamada Keiichi, Nakano Satoshi, Honda Takashi

    Kanzo   Vol. 54 ( 12 ) page: 850 - 853   2013

     More details

    Publishing type:Research paper (scientific journal)   Publisher:The Japan Society of Hepatology  

    We performed percutaneous radio frequency ablation (RFA) therapy by two-step insertion method using VirtuTRAX<sup>TM</sup> (GE Healthcare, USA) instrument navigator. Subjects were 16 patients (23 nodules) with hepatocellular carcinoma. VirtuTRAX<sup>TM</sup> position sensor was attached to the hilt of 14-gauge outer needle. In all cases, we could perform 17- gauge Cool-tip RFA without the positional gap between the virtual tract and the actual needle which was caused by the deflection of the needle. The reasons without causing the positional gap were that the outer needle was more rigid than Cool-tip needle, and that it was inserted using initial insertion of a 21-gauge guided needle. RFA by two-step insertion method using VirtuTRAX<sup>TM</sup> is suggested to be more safe and effective than conventional RFA.

    DOI: 10.2957/kanzo.54.850

    Scopus

    researchmap

  32. An Increase in Lesion Density can Predict Lower Local Recurrence after Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma

    Imai Norihiro, Katano Yoshiaki, Kuzuya Teiji, Honda Takashi, Hayashi Kazuhiko, Ishigami Masatoshi, Itoh Akihiro, Hirooka Yoshiki, Goto Hidemi

    HEPATO-GASTROENTEROLOGY   Vol. 60 ( 125 ) page: 965 - 970   2013

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Hepato-Gastroenterology  

    DOI: 10.5754/hge121229

    Web of Science

    Scopus

    PubMed

    researchmap

  33. Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load

    ARASE Yasuji, SUZUKI Yoshiyuki, SUZUKI Fumitaka, AKUTA Norio, SEZAKI Hitomi, KAWAMURA Yusuke, KOBAYASHI Masahiro, IMAI Norihiro, SEKO Yuya, HOSAKA Tetsuya, MATSUMOTO Naoki, SAITO Satoshi, IKEDA Kenji, KOBAYASHI Mariko, KUMADA Hiromitsu

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 42 ( 8 ) page: 750 - 756   2012.8

     More details

    Publishing type:Research paper (scientific journal)  

  34. Combination therapy with transcatheter arterial infusion chemotherapy using miriplatin and percutaneous radiofrequency ablation for hepatocellular carcinoma

    IMAI Norihiro, IKEDA Kenji, SEKO Yuya, HARA Tasuku, OHNO Atsushi, MATSUMOTO Naoki, KAWAMURA Yusuke, HOSAKA Tetsuya, KOBAYASHI Masahiro, SAITOH Satoshi, SEZAKI Hitomi, AKUTA Norio, SUZUKI Fumitaka, SUZUKI Yoshiyuki, ARASE Yasuji, KUMADA Hiromitsu

    Kanzo   Vol. 53 ( 6 ) page: 351-354 - 354   2012.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Japan Society of Hepatology  

    Miriplatin is a platinum complex developed to treat hepatocellular carcinoma (HCC) via administration into the hepatic artery as a sustained-release suspension in iodized oil. We retrospectively evaluated the efficacy of combination therapy with transcatheter arterial infusion chemotherapy using miriplatin and percutaneous radiofrequency ablation for HCC in 11 patients. Immediately after transcatheter arterial infusion chemotherapy using miriplatin, we performed radiofrequency ablation. The greatest long-axis and short-axis dimensions of the area coagulated after combination therapy were 42 mm (35-80 mm) and 34 mm (32-60 mm), respectively. During follow-up (median 12 months), there was no recurrence from the same subsegment. No serious adverse events were observed. These results suggested that using the combination therapy, it is possible to finish one treatment session for patient with HCC.<br>

    DOI: 10.2957/kanzo.53.351

    researchmap

  35. Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126mg/dL

    MATSUMOTO Naoki, ARASE Yasuji, SEKO Yuya, IMAI Norihiro, KAWAMURA Yusuke, SEZAKI Hitomi, HOSAKA Tetsuya, AKUTA Norio, KOBAYASHI Mariko, KOBAYASHI Masahiro, SUZUKI Yoshiyuki, SAITO Satoshi, SUZUKI Fumitaka, IKEDA Kenji, KUMADA Hiromitsu, AIDA Kaoru, KOBAYASHI Tetsuro

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 42 ( 6 ) page: 558 - 563   2012.6

     More details

    Publishing type:Research paper (scientific journal)  

  36. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderlv patients

    ARASE Yasuji, KOBAYASHI Mariko, SUZUKI Fumitaka, SUZUKI Yoshiyuki, KAWAMURA Yusuke, AKUTA Norio, IMAI Norihiro, KOBAYASHI Masahiro, SEZAKI Hitomi, MATSUMOTO Naoki, SAITO Satoshi, HOSAKA Tetsuya, IKEDA Kenji, KUMADA Hiromitsu, OHMOTO Yuki, AMAKAWA Kazuhisa, HSIEH Shiun Dong, OGAWA Kyoko, TANABE Maho, TSUJI Hiroshi, KOBAYASHI Tetsuro

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 42 ( 3 ) page: 264 - 272   2012.3

     More details

    Publishing type:Research paper (scientific journal)  

  37. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.

    Imai N, Ikeda K, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

    Japanese journal of clinical oncology   Vol. 42 ( 3 ) page: 175 - 82   2012.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/jjco/hyr189

    Scopus

    PubMed

    researchmap

  38. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.

    Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H

    The American journal of gastroenterology   Vol. 107 ( 2 ) page: 253 - 61   2012.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/ajg.2011.327

    Scopus

    PubMed

    researchmap

  39. Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure

    IMAI Norihiro, IKEDA Kenji, SEKO Yuya, MATSUMOTO Naoki, KAWAMURA Yusuke, HOSAKA Tetsuya, KOBAYASHI Masahiro, SAITOH Satoshi, SEZAKI Hitomi, AKUTA Norio, SUZUKI Fumitaka, SUZUKI Yoshiyuki, ARASE Yasuji, KUMADA Hiromitsu

    Nippon Shokakibyo Gakkai Zasshi   Vol. 108 ( 11 ) page: 1872-1878 - 1878   2011.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Gastroenterology  

    Miriplatin is a novel lipophilic platinum complex developed to treat hepatocellular carcinoma (HCC). Although HCC patients frequently have coexisting chronic renal failure, there is no reliable data regarding clinical toxicity of miriplatin in HCC patients with chronic renal failure. We retrospectively evaluated the safety and efficacy of transcatheter arterial chemotherapy with miriplatin in 67 HCC patients with chronic renal failure (estimated glomerular filtration rate [GFR] by the Cockcroft-Gault equation <60m<i>l</i>/min). Estimated GFR within 2 months after miriplatin administration did not decrease significantly by the Wilcoxon signed rank test (pretreatment;46m<i>l</i>/min, 1 month;48m<i>l</i>/min;<i>P</i>=0.019, 2 months;45m<i>l</i>/min;<i>P</i>=0.619 [<i>P</i><0.003 was significant by the Bonferroni correction]). Complete response in terms of tumor necrosis was achieved in 14 of 67 patients and no serious adverse events were observed. These results suggested that transcatheter arterial chemotherapy with miriplatin can be used safely for HCC patients with chronic renal failure.<br>

    DOI: 10.11405/nisshoshi.108.1872

    researchmap

  40. Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure

    Imai N.

    Journal of Japanese Society of Gastroenterology   Vol. 108 ( 11 ) page: 1872-1878   2011.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Scopus

  41. Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy

    ARASE Yasuji, SUZUKI Fumitaka, KAWAMURA Yusuke, SUZUKI Yoshiyuki, KOBAYASHI Masahiro, MATSUMOTO Naoki, AKUTA Norio, SEZAKI Hitomi, HOSAKA Tetsuya, OGAWA Kyoko, IMAI Norihiro, SEKO Yuya, SAITO Satoshi, IKEDA Kenji, KOBAYASHI Mariko, KUMADA Hiromitsu

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 41 ( 10 ) page: 946 - 954   2011.10

     More details

    Publishing type:Research paper (scientific journal)  

  42. A case of intractable hepatic encephalopathy successfully treated by oral administration of vancomycin hydrochloride, with subsequent improvement of hepatic function reserve enabling transcatheter arterial chemoembolization against hepatocellular carcinoma

    Kuzuya T.

    Japanese Journal of Cancer and Chemotherapy   Vol. 38 ( 6 ) page: 995 - 997   2011.6

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Japanese Journal of Cancer and Chemotherapy  

    Scopus

  43. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analogues treatment in chronic hepatitis B

    HOSAKA Tetsuya, SUZUKI Fumitaka, KOBAYASHI Masahiro, SEKO Yuya, IMAI Norihiro, HIRAKAWA Miharu, KAWAMURA Yusuke, SEZAKI Hitomi, AKUTA Norio, SUZUKI Yoshiyuki, SAITOH Satoshi, ARASE Yasuji, IKEDA Kenji, KOBAYASHI Mariko, KUMADA Hiromitsu

    Kanzo   Vol. 52 ( 4 ) page: 255 - 257   2011.6

     More details

    Publishing type:Research paper (scientific journal)   Publisher:The Japan Society of Hepatology  

    Clearance of HBsAg is considered the ultimate goal in the treatment for chronic hepatitis B. We analyzed clinical factors associated with HBsAg clearance during long-term nucleot(s)ide analogue treatment. By univariate analysis, HBV genotype, family history of HBV infection, previous IFN therapy, HBeAg clearance at 6 months, and undetectable HBV DNA at 6 months were significant predictive factors. By multivariate analysis, HBV genotype, previous IFN therapy, HBeAg clearance at 6 months, and undetectable HBV DNA at 6 months were independent and significant predictive factors of HBsAg clearance. We conclude that patients with genotype A have high probability of HBsAg clearance, and it seems that not only the antiviral potential of nucleot(s)ide analogue but host immune response is needed to achieve HBsAg clearance.<br>

    DOI: 10.2957/kanzo.52.255

    Scopus

    researchmap

  44. Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus

    Arase Y

    Hepatology Research   Vol. 41 ( 6 ) page: 524 - 529   2011.6

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Hepatology Research  

    DOI: 10.1111/j.1872-034X.2011.00798.x

    Scopus

    researchmap

  45. Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model.

    Ikeda K, Kobayashi M, Kawamura Y, Imai N, Seko Y, Hirakawa M, Hosaka T, Sezaki H, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

    Liver international : official journal of the International Association for the Study of the Liver   Vol. 31 ( 5 ) page: 692 - 9   2011.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/j.1478-3231.2011.02480.x

    Scopus

    PubMed

    researchmap

  46. Effect of early antiviral agent therapy (NS3 and NS5A inhibitors) in chronic hepatitis C null responders

    SUZUKI Yoshiyuki, SEZAKI Hitomi, AKUTA Norio, SUZUKI Fumitaka, SEKO Hiroya, IMAI Norihiro, HIRAKAWA Miharu, KAWAMURA Yuusuke, HOSAKA Tetsuya, KOBAYASHI Masahiro, SAITOH Satoshi, ARASE Yasuji, IKEDA Kenji, KOBAYASHI Mariko, KUMADA Hiromitsu

    Kanzo   Vol. 52 ( 2 ) page: 147 - 149   2011.4

     More details

    Publishing type:Research paper (scientific journal)   Publisher:The Japan Society of Hepatology  

    To further improve therapeutic effect on chronic hepatitis C, we have administered NS3 inhibitor and NS5A inhibitor together, and examined effects of early antiviral agent therapy. The subjects were five cases where interferon is ineffective (null responders). The NS5A and NS3 inhibitors are oral drugs and were daily administered for 24 weeks. Figure 1 shows time-dependent change of the number of viruses after the therapy started, and rapid decrease of viruses is recognized. Within 12 hours, HCV-RNA decreased by more than 2 log IU/m<i>l</i> in every patient. Two patients became negative for the virus by the 15th day after the therapy started. Furthermore, 80% of cases by the 28th day and all the cases by the 56th day became negative. The new therapy has manifested excellent early antiviral effect.<br>

    DOI: 10.2957/kanzo.52.147

    Scopus

    researchmap

  47. Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.

    Arase Y, Suzuki Y, Suzuki F, Matsumoto N, Akuta N, Imai N, Seko Y, Sezaki H, Kawamura Y, Kobayashi M, Hosaka T, Saito S, Ikeda K, Kobayashi M, Kumada H

    Internal medicine (Tokyo, Japan)   Vol. 50 ( 19 ) page: 2083 - 8   2011

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2169/internalmedicine.50.5767

    Scopus

    PubMed

    researchmap

  48. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.

    Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

    Oncology   Vol. 80 ( 3-4 ) page: 188 - 94   2011

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1159/000328749

    Scopus

    PubMed

    researchmap

  49. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation : A retrospective study of hepatitis C virus-related liver cancer

    IKEDA Kenji, KOBAYASHI Masahiro, SEKO Yuya, IMAI Norihiro, HIRAKAWA Miharu, KAWAMURA Yusuke, SEZAKI Hitomi, HOSAKA Tetsuya, AKUTA Norio, SAITOH Satoshi, SUZUKI Fumitaka, SUZUKI Yoshiyuki, ARASE Yasuji, KUMADA Hiromitsu

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 40 ( 12 ) page: 1168-1175   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  50. Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and Child-Pugh B liver cirrhosis

    IMAI Norihiro, IKEDA Kenji, SEKO Yuya, HIRAKAWA Miharu, KAWAMURA Yusuke, HOSAKA Tetsuya, KOBAYASHI Masahiro, SAITOH Satoshi, SEZAKI Hitomi, AKUTA Norio, SUZUKI Fumitaka, SUZUKI Yoshiyuki, ARASE Yasuji, KUMADA Hiromitsu

    Kanzo   Vol. 51 ( 12 ) page: 758 - 760   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Japan Society of Hepatology  

    Miriplatin is a novel lipophilic platinum complex developed to treat hepatocellular carcinoma (HCC). Although HCC patients frequently have coexisting severe liver cirrhosis, there is no prospective data regarding clinical toxicity of miriplatin in HCC patients with severe cirrhosis. We retrospectively evaluated the safety and efficacy of transcatheter arterial chemotherapy with miriplatin in 34 HCC patients with severe liver cirrhosis (Child-Pugh grade B). An anti-tumor effect of complete response was achieved in 8 of 34 patients and no serious adverse events were observed. These results suggested that transcatheter arterial chemotherapy with miriplatin can be used safety for HCC patients with Child-Pugh B liver cirrhosis.<br>

    DOI: 10.2957/kanzo.51.758

    Scopus

    researchmap

  51. A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy

    Imai N.

    Japanese Journal of Cancer and Chemotherapy   Vol. 37 ( 3 ) page: 527 - 529   2010.3

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Japanese Journal of Cancer and Chemotherapy  

    Scopus

  52. High Incidence of Colonic Perforation During Colonoscopy in Hemodialysis Patients With End-Stage Renal Disease

    Imai Norihiro, Takeda Kinichi, Kuzuya Teiji, Utsunomiya Setsuo, Takahashi Hiroshi, Kasuga Hirotake, Asai Masami, Yamada Michiko, Tanikawa Yutaka, Goto Hidemi

    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY   Vol. 8 ( 1 ) page: 55 - 59   2010.1

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Clinical Gastroenterology and Hepatology  

    DOI: 10.1016/j.cgh.2009.09.029

    Web of Science

    Scopus

    PubMed

    researchmap

  53. A case of hepatitis b-related multiple hepatocellular carcinomas, most of which lead to necrosis possibly due to the implantation of an arterial infusion catheter

    Kuzuya T.

    Japanese Journal of Cancer and Chemotherapy   Vol. 36 ( 12 ) page: 2377 - 2379   2009.11

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Japanese Journal of Cancer and Chemotherapy  

    Scopus

▼display all

Books 2

  1. 肝癌診療ハンドブック ケースで学ぶ集学的治療のコツとセンス

    今井則博, 池田健次( Role: Joint author ,  ケースカンファレンス, 肝癌スクリーニングフローチャート, 各種モダリティの長所と短所, EOB-MRI肝細胞相でのみ低信号結節として指摘できる病変の診断, 肝動脈化学塞栓療法(TACE) 他)

    南江堂  2012 

  2. 劇症肝炎, 病気がみえる vol. 1 消化器 第4版

    今井則博, 荒瀬康司( Role: Joint author ,  劇症肝炎)

    メディックメディア  2010 

     More details

    Language:Japanese

    researchmap

Presentations 16

  1. SUPPRESSION OF FATTY ACID OXIDATION BY THIOESTERASE SUPERFAMILY MEMBER 2 IN SKELETAL MUSCLE PROMOTES HEPATIC STEATOSIS AND INSULIN RESISTANCE

    Imai Norihiro, Alves-Bezerra Michele, Li Yingxia, Cohen David E.

    HEPATOLOGY 

     More details

    Event date: 2019.10

    Language:English   Presentation type:Oral presentation (general)  

  2. Muscle-Specific Metabolic Regulation By Thioesterase Superfamily Member 2 in the Pathogenesis of Nonalcoholic Fatty Liver Disease

    Imai Norihiro, Cohen David E.

    HEPATOLOGY 

     More details

    Event date: 2018.10

    Language:English   Presentation type:Oral presentation (general)  

  3. Hepatocyte-Specific Depletion of Ubiquitin Regulatory X Domain-Containing 8 (UBXD8) Induces Marked Fibrosis in Mice Fed a Short-Term Non-Alcoholic Steatohepatitis (NASH) Model Diet

    Imai Norihiro, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Hayashi Kazuhiko, Ishigami Masatoshi, Hirooka Yoshiki, Fujimoto Toyoshi, Goto Hidemi

    HEPATOLOGY 

     More details

    Event date: 2016.10

    Language:English   Presentation type:Oral presentation (general)  

  4. Hepatocyte-specific depletion of UBXD8 accelerates fibrosis in a mouse non-alcoholic steatohepatitis model

    Imai Norihiro, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Hayashi Kazuhiko, Ishigami Masatoshi, Hirooka Yoshiki, Fujimoto Toyoshi, Goto Hidemi

    HEPATOLOGY 

     More details

    Event date: 2015.10

    Language:English   Presentation type:Oral presentation (general)  

  5. Hepatocyte-specific deletion of UBXD8 induces periportal steatosis after high-fat diet feeding

    Imai Norihiro, Suzuki Michitaka, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Hayashi Kazuhiko, Ishigami Masatoshi, Fujimoto Toyoshi, Goto Hidemi

    HEPATOLOGY 

     More details

    Event date: 2014

    Language:English   Presentation type:Oral presentation (general)  

  6. Trimming the Fat: Acetyl-CoA Carboxylase Inhibition for the Management of NAFLD

    Imai Norihiro, Cohen David E

    HEPATOLOGY  2018.12  Hepatology

     More details

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  7. Thioesterase Superfamily Member 1 Undergoes Stimulus-coupled Reorganization to Regulate Metabolic Activity in Brown Adipose Tissue

    Li Yue, Imai Norihiro, Goyal Samaksh, Nicholls Hayley, Krisko Tibor, Baqai Mahnoor, Ang Lay-Hong, Tillman Matthew, Ortlund Eric, Cohen David, Hagen Susan

    FASEB JOURNAL  2020.4 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  8. GUT MICROBIOTA ASSOCIATED WITH THE DIFFERENCE BETWEEN PATIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA IN CHRONIC LIVER DISEASE

    Honda Takashi, Ishigami Masatoshi, Yamamoto Kenta, Ito Takanori, Imai Norihiro, Ishizu Yoji, Fujishiro Mitsuhiro

    HEPATOLOGY  2020.11 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  9. IMPROVEMENT OF LIVER FUNCTIONAL RESERVE AFTER SVR IN HCV-PATIENTS WITH COMPENSATED, SEVERE FIBROSIS BY IFN-FREE, DAA COMBINATION TREATMENT-IMPACT OF PRETREATMENT SERUM AFP LEVELS

    Ishigami Masatoshi, Honda Takashi, Ishizu Yoji, Imai Norihiro, Ito Takanori, Yamamoto Kenta, Fujishiro Mitsuhiro

    HEPATOLOGY  2020.11 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  10. MODELING NAFLD IN HIGH FAT FED MICE: IDENTIFICATION OF A THRESHOLD VALUE FOR HEPATIC STEATOSIS AND METABOLIC DYSFUNCTION

    Imai Norihiro, Cohen David E

    HEPATOLOGY  2020.11 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  11. SAFETY AND EFFICACY OF PERCUTANEOUS RADIOFREQUENCY ABLATION FOR HEPATOCELLULAR CARCINOMA PATIENTS WITH HEMOPHILIA

    Yamamoto Takafumi, Ishigami Masatoshi, Yamamoto Kenta, Ito Takanori, Imai Norihiro, Lshizu Yoji, Honda Takashi, Fujishiro Mitsuhiro

    HEPATOLOGY  2020.11 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  12. Them1 Binds to Free Fatty Acids and is Allosterically Regulated by Lysophosphatidylcholine to Control Fatty Acyl-CoA Hydrolysis in Brown Adipose Tissue

    Tillman Matthew, Li Yue, Khadka Manoj, Imai Norihiro, Adhiyaman Akshitha, Juneja Puneet, Hagen Susan, Cohen David, Ortlund Eric

    FASEB JOURNAL  2020.4 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  13. GUT MICROBIOTA ASSOCIATED WITH THE DIFFERENCE BETWEEN PATIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA IN CHRONIC LIVER DISEASE

    Honda Takashi, Ishigami Masatoshi, Yamamoto Kenta, Ito Takanori, Imai Norihiro, Ishizu Yoji, Fujishiro Mitsuhiro

    HEPATOLOGY  2020.11 

     More details

    Presentation type:Oral presentation (general)  

  14. Thioesterase Superfamily Member 1 Undergoes Stimulus-coupled Reorganization to Regulate Metabolic Activity in Brown Adipose Tissue

    Li Yue, Imai Norihiro, Goyal Samaksh, Nicholls Hayley, Krisko Tibor, Baqai Mahnoor, Ang Lay-Hong, Tillman Matthew, Ortlund Eric, Cohen David, Hagen Susan

    FASEB JOURNAL  2020.4 

     More details

    Presentation type:Oral presentation (general)  

  15. Them1 Binds to Free Fatty Acids and is Allosterically Regulated by Lysophosphatidylcholine to Control Fatty Acyl-CoA Hydrolysis in Brown Adipose Tissue

    Tillman Matthew, Li Yue, Khadka Manoj, Imai Norihiro, Adhiyaman Akshitha, Juneja Puneet, Hagen Susan, Cohen David, Ortlund Eric

    FASEB JOURNAL  2020.4 

     More details

    Presentation type:Oral presentation (general)  

  16. IMPROVEMENT OF LIVER FUNCTIONAL RESERVE AFTER SVR IN HCV-PATIENTS WITH COMPENSATED, SEVERE FIBROSIS BY IFN-FREE, DAA COMBINATION TREATMENT-IMPACT OF PRETREATMENT SERUM AFP LEVELS

    Ishigami Masatoshi, Honda Takashi, Ishizu Yoji, Imai Norihiro, Ito Takanori, Yamamoto Kenta, Fujishiro Mitsuhiro

    HEPATOLOGY  2020.11 

     More details

    Presentation type:Oral presentation (general)  

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 3

  1. 臓器特異的なUBXD8の機能を主軸としたアルコール性肝障害の病態形成メカニズム

    Grant number:21KK0277  2021

    科学研究費助成事業  国際共同研究加速基金(国際共同研究強化(A))

    今井 則博

      More details

    Authorship:Principal investigator 

    Grant amount:\15600000 ( Direct Cost: \12000000 、 Indirect Cost:\3600000 )

  2. アルコール性肝障害におけるUBXD8機能の解明

    Grant number:21K15946  2021.4 - 2025.3

    若手研究

    今井 則博

      More details

    Authorship:Principal investigator 

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

  3. マイオカインによる臓器相関に着目した新規NAFLD治療ターゲットの探索

    Grant number:20K22898  2020.9 - 2022.3

    日本学術振興会  科学研究費助成事業 研究活動スタート支援  研究活動スタート支援

    今井 則博

      More details

    Authorship:Principal investigator 

    Grant amount:\2860000 ( Direct Cost: \2200000 、 Indirect Cost:\660000 )

    骨格筋はマイオカインと総称されるペプチドの分泌を通じて、肝臓を含む全身の代謝臓器との臓器間コミュニケーションにおいて重要な役割を果たしている。近年、研究代表者はマウスモデルにおいて骨格筋における脂肪酸のβ酸化が臓器を超えて脂肪肝、インスリン抵抗性、肥満の発症に関与していること、また骨格筋が代謝状態に応じて複数のマイオカインを分泌し肝臓からの超低密度リポタンパク質(VLDL)分泌を調節していることを明らかにした。これらの知見は骨格筋の脂肪酸代謝が全身の糖代謝、脂質代謝において重要な役割を果たしていること、骨格筋がマイオカインを通じて過栄養時の脂肪肝、肥満の発症に寄与していることを示唆している。

    researchmap